Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints

Key TakeawaysThe experimental COVID-19/flu vaccine from Pfizer and BioNTech missed one of two key endpoints in a Phase 3 study.The companies reported that while the shot worked against COVID-19 and influenza A, it fell short versus influenza B.Pfizer and BioNTech said they are evaluating adjustments to the vaccine. Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' co ...